What is the engineered probiotic for ulcerative colitis?

It is a modified version of E coli Nissle 1917 designed to use tetrathionate, an inflammatory by product, as an energy source in inflamed bowel conditions.

Is this treatment available for ulcerative colitis patients now?

No. The current data is preclinical and comes from animal studies. Human safety trials are planned.

Will engineered probiotics replace biologics in ulcerative colitis?

They are unlikely to replace biologics. They may eventually complement biologics by modifying the bowel environment and supporting disease stability.

Engineered Probiotic for Ulcerative Colitis 2026 | UK-Trained Gastroenterologist in Dubai

Q: Why is tetrathionate important?

Tetrathionate is produced in the gut during inflammation. The engineered strain is designed to use it as fuel, giving it a survival advantage in an inflamed colon.

By Dr Pranab Gyawali, Consultant Gastroenterologist
Published: 02 March 2026

A newly published preclinical study has described a next generation engineered probiotic for ulcerative colitis. This is not a new biologic. It is a modified strain of E coli Nissle 1917 designed to survive in the inflamed colon.

This matters because ulcerative colitis treatment has traditionally focused on suppressing inflammation through medicines such as anti TNF therapy, IL 23 inhibitors and JAK inhibitors. This research approaches the problem differently. It asks whether we can change the environment inside the bowel itself.

Video explanation

What is the main idea?

E coli Nissle 1917 is not new. It is a probiotic strain that has been known for more than 100 years and has been studied in ulcerative colitis, especially for remission maintenance.

The new study is different because researchers engineered this strain so that it can use tetrathionate, a chemical by product of inflammation, as a fuel source.

In simple terms, a standard probiotic may struggle inside an inflamed colon. This engineered strain is designed to gain an advantage in that same inflammatory environment.

Why does this matter for patients with ulcerative colitis?

Many patients ask about probiotics, diet and microbiome treatments in ulcerative colitis. The honest answer is that traditional probiotics have often produced mixed or modest results.

However, this research represents a different category. It is not generic probiotic supplementation. It is closer to a precision designed live biotherapeutic, where the organism is modified for a specific inflammatory environment.

Visual explanation

Engineered E coli Nissle 1917 TTR thriving on tetrathionate in inflamed colon compared with standard E coli Nissle 1917 in ulcerative colitis

Figure: Standard E coli Nissle 1917 struggles in an inflamed colon, whereas engineered E coli Nissle 1917 TTR can thrive in inflammation by feeding on tetrathionate. This is a simplified illustration of the preclinical concept.

Quick summary of the study

Question	Summary
What was studied?	An engineered version of E coli Nissle 1917 called E coli Nissle 1917 TTR.
What was it engineered to do?	Use tetrathionate, an inflammation related by product, as an energy source.
What condition is this aimed at?	Ulcerative colitis.
What type of evidence is available?	Preclinical animal data, not human efficacy data.
What is planned next?	Human safety testing is planned.

What did the animal studies show?

The study reported results from animal models of colitis. These included mouse models of severe colitis and a porcine model of acute colitis.

The engineered strain showed better colonisation and stronger anti inflammatory effects than the unmodified parent strain. In the porcine model, untreated animals became severely unwell, whereas treated animals showed improved clinical and tissue findings.

Finding	Why it matters
Better survival in inflammatory conditions	The engineered strain was designed to function in an inflamed bowel environment.
Improved colonisation	Colonisation is one of the major limitations of traditional probiotics in active inflammation.
Improved mucosal integrity	This suggests possible protection of the bowel lining in preclinical models.
Reduced inflammatory severity	This supports the concept that microbiome derived therapies may influence inflammatory activity.

Important caution

This is still animal data. It is not yet proof that this treatment works in humans with ulcerative colitis.

Many therapies look promising in animal studies but do not always translate into human benefit. For that reason, the next important step is human safety testing, followed by carefully designed clinical efficacy trials.

How is this different from biologics?

Biologics and advanced therapies usually work by targeting immune pathways. Examples include anti TNF medicines, IL 23 inhibitors and JAK inhibitors.

The engineered probiotic concept is different. It does not primarily aim to block one inflammatory pathway. Instead, it attempts to modify the bowel environment in which inflammation occurs.

Current treatment approach	Engineered microbiome approach
Blocks immune signals such as TNF or IL 23	Modifies the inflammatory environment inside the colon
Works through immune pathway suppression	Works through targeted microbial metabolism
Established role in moderate to severe ulcerative colitis	Still experimental and preclinical
Used in clinical practice now	Requires human safety and efficacy trials

Will this replace biologics?

In my view, it is unlikely that engineered probiotics will replace biologics in the near future.

The more realistic possibility is that microbiome derived therapies may eventually complement biologics. They may help stabilise the bowel environment, reduce flare tendency or support longer term disease control. That remains to be proven in human studies.

Why this is strategically important

For years, probiotics in inflammatory bowel disease have been viewed as weak or inconsistent. That criticism has often been fair, especially when discussing generic probiotics.

But the field is changing. We are moving from broad probiotic supplements toward more targeted live biotherapeutic products. These are designed with a specific biological purpose.

This is why the study is interesting. It reflects a larger shift in ulcerative colitis research, from only blocking inflammation to also thinking about the microbiome and bowel environment that shape immune behaviour.

View study here

Frequently asked questions

Is this engineered probiotic available now?

No. It is not currently available as a treatment for ulcerative colitis. The published data is preclinical.

What is tetrathionate?

Tetrathionate is a chemical by product associated with intestinal inflammation. The engineered strain is designed to use it as an energy source.

Does this mean probiotics work for ulcerative colitis?

Not all probiotics are the same. Generic probiotics and engineered live biotherapeutics should not be treated as equivalent. This study is about a specifically engineered strain, not a standard over the counter probiotic.

Could this help people already on biologics?

That is not proven yet. In the future, microbiome based therapies may be studied alongside biologics, but human clinical trials are needed first.

Why is this relevant to microbiome medicine?

It shows how microbiome science is moving from general supplementation toward targeted interventions designed for specific disease environments.

Final thought

This is early research, but it is important because it shows the direction of travel. Ulcerative colitis treatment may not only be about suppressing immune pathways. It may also involve changing the bowel environment that drives inflammation.

Engineered Probiotic for Ulcerative Colitis 2026

REQUEST AN APPOINTMENT

Dr. Gyawali is exclusively available at

Mubadala Health – Jumeirah, Dubai

Menu Links